New drug IBI129 shows promise in early trial for Hard-to-Treat cancers

NCT ID NCT05991349

Completed Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 03, 2026 · Last updated Jun 17, 2026 · Updated 18 times

Summary

This study tested a new drug, IBI129, in 180 adults with advanced solid tumors that could not be removed by surgery. The goal was to find the safest dose and see if the drug can shrink tumors. The trial is complete, and results will help decide if further testing is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Chris O'Brien Lifehouse

Camperdown, New South Wales, 2050, Australia
Hubei Cancer Hospital

Wuhan, Hubei, China
Shandong Cancer Hospital

Jinan, Shandong, 250117, China
St George private Hospital

Kogarah, New South Wales, 2217, Australia
The First Hospital of Jilin University

Changchun, Jilin, 130021, China
Tianjin Medical university cancer institute & Hospital

Tianjin, Tianjin Municipality, 300000, China
Wollongong Hospital

Wollongong, New South Wales, 2500, Australia

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR